关于我们About us

创始于2018年8月16日,由瑞典科学家Sven Skog教授和Ellen He博士,以及中国科学家李劲博士创办,是中国深圳首家由深圳市科学技术协会主管的,专注生物医学、医学大数据和精准医学技术研究开发的非营利性科研机构。通过构建精准医学交流合作的平台,与全球医疗健康领域的有识之士携手共进,努力融合产、学、医、研、用多方力量,推动精准医疗科学研究与成果应用,催生精准医疗领域新技术、新模式,增进人类健康福祉。

Shenzhen Ellen-Sven Precision Medicine Institute was established by Swedish scientists, Prof. Sven Skog and Dr. Ellen He, and a Chinese scientist, Dr. Jin Li, on 16 August 2018. The Institute is the first non-profit organization of precision medicine research in Shenzhen, China, and is supervised by the Shenzhen Association for Science and Technology. It specializes in research related to biomedical, medical big data, and precision medicine technology. By creating a platform for precision medicine communication and cooperation, the institute collaborates with global experts in medical and health fields to integrate the strengths of production, study, medicine, research, and application, to promote the research and application of precision medicine, and to develop new technologies and care models in the precision medicine field. The institute’s ambition is to use research to help enhance human health and well-being.

研究所名誉所长,原瑞典卡罗琳斯卡医学院(诺贝尔生理学或医学奖评审单位)临床研究中心肿瘤分子实验室主任Sven Skog教授表示“精准医学作为一项前沿的医学理念已在瑞典等国家有过多年的成功实践,希望研究所的成立能成为中国精准医学发展新的起点,通过联合开展国际前沿研究,形成重大原始创新成果并转化应用,最终造福世界人民”。

Prof. Sven Skog, the Honorary Director of the institute and the former Director of the Tumor Molecular Laboratory at the Clinical Research Center of Karolinska Institute in Sweden, stated that “Precision medicine, as an advanced medical concept, has been successfully practiced in Sweden and other countries for many years. It is hoped that the establishment of the institute can become a new starting point for the development of precision medicine in China. By jointly conducting international cutting-edge research, significant original innovation results can be formed and applied, ultimately benefiting people around the world.”

研究所成立时间虽短,但已与多家医疗和科研机构达成科研合作并产出科研成果。例如,与常州市肿瘤医院(苏州大学附属常州肿瘤医院)合作开展了细胞增殖动力生物学标志物胸苷激酶1应用于影像学不可见肿瘤检测的研究、与北京林业大学北京市森林害虫防治重点实验室合作开展了抗新冠病毒卵黄免疫球蛋白(IgY)抗体的制备与转化研究、以及与中山大学肿瘤防治中心合作开展了结直肠癌的预后研究。

Although the institute has been established for a short time, it has already collaborated with multiple medical and research institutions and produced research results. For example, in collaboration with the Changzhou Tumor Hospital, the institute conducted research on the use of the cell proliferation biomarker thymidine kinase 1 for the detection of image-invisible tumors. Additionally, in collaboration with the Beijing Key Laboratory of Forest Pest Control at Beijing Forestry University, the institute conducted research on the preparation and transformation of anti-COVID-19 coronavirus immunoglobulin Y (IgY) antibodies. The institute has also collaborated with the Sun Yat-sen University Cancer Center on prognostic research on colorectal cancer.

2023年1月9日,原复旦大学附属华东医院内分泌科主任医师、内分泌代谢病专家汪海东教授正式成为研究所行政所长,为研究所开展慢病管理方向的研究极大助力。在他的带领下,研究所开始整合各方面资源,逐步推进慢病方向的课题、助力健康中国战略落地实施。2023年3月7日,汪海东教授携研究所专家团队成功助力武汉疾控与中国健康促进基金会联合开展“健康促进社区行——肿瘤防治与康复”项目,为研究所开展肿瘤等重大慢病管理的基层医疗研究走好了第一步。

On 9 January 2023, Prof. Haidong Wang, a renowned endocrinologist and metabolic disease expert who was formerly the director of the Endocrinology Department at Fudan University-affiliated Huadong Hospital, officially became the administrative director of the institute, greatly boosting the institute’s research efforts in the field of chronic disease management. Under his leadership, the institute began to integrate various resources and gradually advance research on chronic disease management, thereby supporting the implementation of the Healthy China policy. On 7 March 2023, Prof. Haidong Wang and the team of experts at the institute successfully assisted the Wuhan Center for Disease Control and Prevention and the China Health Promotion Foundation in launching the “Healthy Community Promotion – Cancer Prevention and Rehabilitation” project, taking the first step towards the institute’s research on primary care for major chronic diseases such as cancer.